Measles (Rubeola) Antibodies, IgM

CPT: 86765
Updated on 10/14/2024

Synonyms

  • Measles IgM
  • Rubeola IgM

Expected Turnaround Time

3 - 5 days

3 - 5 days


Related Documents


Specimen Requirements


Specimen

Serum


Volume

1 mL


Minimum Volume

0.5 mL (Note: This volume does not allow for repeat testing.)


Container

Gel-barrier tube, red-top tube or serum transfer tube


Collection

If tube other than a gel-barrier tube is used, transfer serum to a plastic transport tube.


Storage Instructions

Refrigerate.


Stability Requirements

TemperaturePeriod
Room temperatureUnstable
Refrigerated7 days
Frozen6 months
Freeze/thaw cyclesStable x1

Stability determined by manufacturer or literature reference.


Causes for Rejection

Grossly hemolyzed, lipemic and icteric samples; heat-inactivated samples; samples with visible particulate matter or gross bacterial contamination


Test Details


Use

This test is invaluable for determining acute-phase infection with the rubeola (measles) virus by detecting the presence of IgM antibodies. It also plays a crucial role in identifying individuals who are not immune to the virus, enabling timely preventive measures. By measuring IgM antibodies the molecular detection of virus, healthcare providers can accurately diagnose current infections and recognize those at risk, ensuring appropriate medical responses and public health interventions.

Measles is extremely contagious, especially among unvaccinated individuals, and spreads through direct contact with aerosolized droplets or respiratory secretions. Immunocompromised individuals, pregnant women and those with nutritional deficiencies face a higher risk of severe complications, such as pneumonia and central nervous system involvement, when infected with the measles virus. The national measles vaccination program, launched in 1963, has reduced measles incidence to fewer than 0.5 cases per 1,000,000 people in the U.S., eliminating its endemic status. However, outbreaks still occur due to exposure of nonimmune individuals or waning immunity from infected travelers. The presence of IgM-class antibodies suggests recent infection but should not be used alone to diagnose measles infection. The CDC recommends to obtain both a serum sample (for IgM antibody) and a throat swab or nasopharyngeal swab (for PCR) from patients suspected to have measles at first contact with them. Urine samples may also contain virus. When feasible to do so, collecting both respiratory and urine samples for PCR can increase the likelihood of detecting measles virus.


Limitations

The absence of IgM-class antibodies suggests lack of an acute phase infection with measles virus. However, serology may be negative for IgM-class antibodies in early disease, and results should be interpreted in the context of clinical findings.

Testing for IgM-class antibodies to measles should be limited to patients with clinically compatible disease.


Methodology

Immunofluorescence


References

Measles (Rubeola). Centers for Disease Control and Prevention website: https://www.cdc.gov/measles/hcp/clinical-overview/?CDC_ AAref_Val=https://www.cdc.gov/measles/hcp/index.html. Updated July 15, 2024. Accessed August 2024.

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf